Melita Kenealy

598 total citations
20 papers, 269 citations indexed

About

Melita Kenealy is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Melita Kenealy has authored 20 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 8 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Melita Kenealy's work include Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Melita Kenealy is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Melita Kenealy collaborates with scholars based in Australia, United Kingdom and New Zealand. Melita Kenealy's co-authors include H. Miles Prince, David Westerman, M Wolf, Constantine S. Tam, John F. Seymour, J.F. Seymour, Dennis Carney, Neil Came, A. Milner and David Ritchie and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Leukemia.

In The Last Decade

Melita Kenealy

20 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melita Kenealy Australia	10	132	109	77	73	69	20	269
Marie-Pierre Gourin France	8	107 0.8×	46 0.4×	46 0.6×	42 0.6×	41 0.6×	14	201
Sebastian Saur Germany	8	73 0.6×	75 0.7×	29 0.4×	72 1.0×	16 0.2×	26	259
Mojdeh Naghashpour United States	10	112 0.8×	43 0.4×	61 0.8×	47 0.6×	28 0.4×	14	275
Catherine Hildyard United Kingdom	7	67 0.5×	102 0.9×	144 1.9×	25 0.3×	41 0.6×	12	223
Maaike de Bie Netherlands	9	127 1.0×	54 0.5×	103 1.3×	56 0.8×	86 1.2×	17	321
Jennifer Poon United States	10	39 0.3×	67 0.6×	37 0.5×	82 1.1×	131 1.9×	16	278
H. Goldschmidt Germany	7	271 2.1×	29 0.3×	31 0.4×	214 2.9×	117 1.7×	8	356
Olga Grishina Germany	7	161 1.2×	60 0.6×	46 0.6×	53 0.7×	46 0.7×	16	269
A. Hellmann Poland	8	60 0.5×	180 1.7×	131 1.7×	24 0.3×	45 0.7×	28	257
Carmen Sanzo Spain	5	166 1.3×	84 0.8×	55 0.7×	48 0.7×	24 0.3×	5	211

Countries citing papers authored by Melita Kenealy

Since Specialization

Citations

This map shows the geographic impact of Melita Kenealy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melita Kenealy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melita Kenealy more than expected).

Fields of papers citing papers by Melita Kenealy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melita Kenealy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melita Kenealy. The network helps show where Melita Kenealy may publish in the future.

Co-authorship network of co-authors of Melita Kenealy

This figure shows the co-authorship network connecting the top 25 collaborators of Melita Kenealy. A scholar is included among the top collaborators of Melita Kenealy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melita Kenealy. Melita Kenealy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tiong, Ing Soo, William Stevenson, Meaghan Wall, et al.. (2023). Favorable outcomes of DDX41‐mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide. SHILAP Revista de lepidopterología. 4(4). 1212–1215. 2 indexed citations

Song, Yuqin, Zengjun Li, Ling Li, et al.. (2023). GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 1719–1719. 10 indexed citations

McQuilten, Zoe, Lucy Busija, John F. Seymour, et al.. (2021). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia & lymphoma. 63(3). 676–683. 2 indexed citations

Chee, Lynette, David Ritchie, Mandy Ludford‐Menting, et al.. (2021). Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). European Journal Of Haematology. 108(4). 342–353. 2 indexed citations

Horvath, Noemi, Andrew Spencer, Melita Kenealy, et al.. (2019). Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leukemia & lymphoma. 60(9). 2122–2133. 13 indexed citations

Brooker, Joanne, Jeremy Millar, H. Miles Prince, et al.. (2019). A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patients. Palliative & Supportive Care. 18(2). 130–140. 25 indexed citations

Kenealy, Melita, Mark Hertzberg, Kerry Taylor, et al.. (2018). Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica. 104(4). 700–709. 13 indexed citations

Kenealy, Melita, Nigel Patton, Robin Filshie, et al.. (2016). Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia & lymphoma. 58(2). 298–307. 13 indexed citations

Kenealy, Melita, William G. Stetler‐Stevenson, Richard Eek, et al.. (2015). 13 THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. Leukemia Research. 39. S5–S5. 5 indexed citations

10.

Dickinson, Michael, Kirsten Herbert, Caroline T. Sardjono, et al.. (2014). Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML. Blood. 124(21). 4657–4657. 4 indexed citations

11.

Dickinson, Michael, Caroline T. Sardjono, Emma Link, et al.. (2013). P-276 High doses of eltrombopag are well-tolerated in conjunction with azacitidine and demonstrate encouraging activity in patients with MDS and AML. Leukemia Research. 37. S147–S147. 1 indexed citations

12.

Kenealy, Melita, J.F. Seymour, William G. Stetler‐Stevenson, et al.. (2013). P-272 The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial. Leukemia Research. 37. S145–S145. 1 indexed citations

13.

Bird, Robert, Melita Kenealy, Cecily Forsyth, et al.. (2012). When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?. Internal Medicine Journal. 42(4). 450–455. 9 indexed citations

14.

Carney, Dennis, David Westerman, Constantine S. Tam, et al.. (2010). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 24(12). 2056–2062. 68 indexed citations

15.

Kenealy, Melita, John F. Seymour, Alvin Milner, et al.. (2009). The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).. Blood. 114(22). 1749–1749. 2 indexed citations

16.

Bishton, Mark, Melita Kenealy, Ricky W. Johnstone, Walid Rasheed, & H. Miles Prince. (2007). Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Review of Anticancer Therapy. 7(10). 1439–1449. 27 indexed citations

17.

Kenealy, Melita & J.F. Seymour. (2007). 12 Treatment of myelodysplastic syndromes with azacitidine and thalidomide. Leukemia Research. 31. S7–S8. 1 indexed citations

18.

Lane, Steven, Julie Crawford, Melita Kenealy, et al.. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia & lymphoma. 47(9). 1813–1817. 18 indexed citations

19.

Tam, Constantine S., J.F. Seymour, H. Miles Prince, et al.. (2006). Treatment-related myelodysplasia following fludarabine combination chemotherapy.. PubMed. 91(11). 1546–50. 52 indexed citations

20.

Lane, Steven, Julie Crawford, Melita Kenealy, et al.. (2005). Pegfilgrastim Compared to Granulocyte Colony Stimulating Factor (G-CSF) with Hyper-CVAD Chemotherapy Regimen for Aggressive Lymphoid Malignancy.. Blood. 106(11). 4274–4274. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact